Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

Analysts expect DexCom to report earnings of $0.6459 per share on revenue of $1.24 billion for the quarter ended December 2025. That would mark a sequential improvement from the third quarter’s $0.61 ...

The U.S. Centers for Medicare & Medicaid Services (CMS) has opted to cover the Freestyle Libre System from Abbott Laboratories for insulin-dependent diabetes patients. The system, which was just ...

It’s buff versus buffet in the latest DTC ad battle of continuous glucose monitors. While Dexcom continues its blood-sugar monitoring campaign with musician and heartthrob Nick Jonas, Abbott takes a ...